Sarah Schlesinger on the Humanity Behind AIDS Research
Dr. Sarah J. Schlesinger has been actively engaged in HIV/AIDS and HIV vaccine research for over ten years. She is currently conducting clinical trials to test a new vaccine called ADMVA, designed to stimulate immune responses and thereby prevent HIV from ever being contracted. A graduate of Wellesley College and Rush Medical College, Schlesinger has been interested in medical science since she was a teenager. As a high school student attending a lecture at Rockefeller University, she boldly asked scientist Ralph Steinman for a job in his laboratory.
Schlesinger worked in Steinman's lab just a few years after he and Zanvil Cohn published their famous discovery of dendritic cells. She then went on to head her own dendritic cell lab at Walter Reed Hospital from 1990 to 2002. With new knowledge about the ability of dendritic cells to orchestrate the body's immune response, Schlesinger and her colleagues are attempting to develop customized immune therapies to target specific infections such as HIV/AIDS, malaria and influenza; certain cancers; and autoimmune diseases.
Question: What is like working with the volunteers?
Sarah Schlesinger: The work that I do is all with normal volunteers. Our vaccines are all in early phase trials, so it’s with people who are uninfected. So I’m working with people who are coming forward of their own good will to volunteer to participate in a HIV vaccine trial. They’re rolling up their arms to develop the vaccine, which is, you know, every time I say that I get goose bumps, because that’s a really a brave thing to do. That’s a non-trivial thing to do. And, in fact, I have been in the lab at the RAIR.
I had worked on vaccine trials but I had supervised them. I hadn’t actually conducted them myself. I had been running a lab, and when I came back to the Rockefeller, I don’t know, six years ago, and to start to doing this work, my biggest worry was what we call recruitment. How were we going to get people to come forward to volunteer? And there had actually been things from the NIH published in the New York Times about how hard it was, and how this was the limiting factor in developing AIDS vaccines, and I was literally losing sleep about it. Like so many things, what you worry about isn’t the thing that gets you.
We put an ad in The Village Voice and the AM New York, and there were going to be 40 people in the trial. We had 400 calls the first day. So it isn’t always that easy and many of the people weren’t really able to participate for one reason or another, but the will here in New York to participate in our vaccine trails has been overwhelming to us. And, you know, I feel like it’s like a Hallmark Card moment, but nothing prepared me for that. And I think the reason that that is, is that New York was hit by HIV in a way like no other city in the developed world. There were more cases here than there were in San Francisco and Miami together in the ‘80s.
And so there’s been some work done on this by colleagues, particularly in Kenya and Thailand, that the thing that predicts people participating in HIV vaccine trials is being either part of an affected community or having watched a friend or loved one die, because they want to do. This is something one can really do to make a difference. And so 30 to 40% of our volunteers are what we call affected by the epidemic. So they are either members of the community or have had a friend or loved one die, and they’re doing it for that reason. So it is tremendously inspiring. I have a great deal of respect for our volunteers and I enjoy interacting with them. For me, because I was in the lab, and I didn’t see patients, it reminded me of why I’m a physician. And I love that. When you set with a patient and you look them in the eye as a physician everything is different.
And I always say when I teach, we wear two hats. We wear that of physician and that of scientist. But the physician always has to come first. The day that it doesn’t come first is the day you have to leave, because you can no longer participate if your physician hat doesn’t come first.
Recorded on: June 10, 2008
Schlesinger respects those who volunteer as research subjects to help discover an AIDS vaccine.
A guide to making difficult conversations possible—and peaceful—in an increasingly polarized nation.
- How can we reach out to people on the other side of the divide? Get to know the other person as a human being before you get to know them as a set of tribal political beliefs, says Sarah Ruger. Don't launch straight into the difficult topics—connect on a more basic level first.
- To bond, use icebreakers backed by neuroscience and psychology: Share a meal, watch some comedy, see awe-inspiring art, go on a tough hike together—sharing tribulation helps break down some of the mental barriers we have between us. Then, get down to talking, putting your humanity before your ideology.
- The Charles Koch Foundation is committed to understanding what drives intolerance and the best ways to cure it. The foundation supports interdisciplinary research to overcome intolerance, new models for peaceful interactions, and experiments that can heal fractured communities. For more information, visit charleskochfoundation.org/courageous-collaborations.
Progressive America would be half as big, but twice as populated as its conservative twin.
- America's two political tribes have consolidated into 'red' and 'blue' nations, with seemingly irreconcilable differences.
- Perhaps the best way to stop the infighting is to go for a divorce and give the two nations a country each
- Based on the UN's partition plan for Israel/Palestine, this proposal provides territorial contiguity and sea access to both 'red' and 'blue' America
A federal judge ruled that the Trump administration likely violated the reporter's Fifth Amendment rights when it stripped his press credentials earlier this month.
- Acosta will be allowed to return to the White House on Friday.
- The judge described the ruling as narrow, and didn't rule one way or the other on violations of the First Amendment.
- The case is still open, and the administration may choose to appeal the ruling.
SMARTER FASTER trademarks owned by The Big Think, Inc. All rights reserved.